Next-Generation Small-Molecule ALK Inhibitors for Non-Small Cell Lung Cancer Treatment
This study reports the rational design, synthesis, and evaluation of novel ferulic acid–based hydrazide derivatives as ALK inhibitors for non-small cell lung cancer, identifying FBH4 as the most potent and promising lead candidate with an IC₅₀ of 71.33 µM/ml that rivals crizotinib.